Table 1.
Baseline Characteristics Across Quartiles of Uric Acid (mg/dL) in the Random Cohort
| Q1: 2.6 to 5.0 |
Q2: 5.1 to 5.8 |
Q3: 5.9 to 6.6 |
Q4: 6.7 to 13.6 |
||
|---|---|---|---|---|---|
| Characteristics | (n = 297) | (n = 379) | (n = 337) | (n = 370) | p Value |
| Mean ± SD | |||||
| Age (years) | 73.8 ± 5.8 | 73.7 ± 5.6 | 73.6 ± 6 | 74.1 ± 6.1 | 0.598 |
| BMI (kg/m2) | 26.7 ± 3.6 | 27.3 ± 3.6 | 27.1 ± 3.3 | 28.3 ± 4.0 | <0.0001 |
| Total hip BMD (g/cm2) | 0.929 ± 0.146 | 0.943 ± 0.139 | 0.948 ± 0.134 | 0.981 ± 0.144 | 0.0003 |
| Uric acid mg/dL | 4.4 ± 0.5 | 5.5 ± 0.2 | 6.2 ± 0.2 | 7.6 ± 1.0 | <0.0001 |
| 25(OH) total vitamin D (ng/mL) | 25.5 ± 7.6 | 25.1 ± 8.1 | 25.5 ± 7.6 | 24.8 ± 8.6 | 0.590 |
| Total intact PTH (pg/mL) | 29.1 ± 12.3 | 30.7 ± 11.7 | 32.7 ± 13.2 | 40.9 ± 46.1 | <0.0001 |
| eGFR (mL/min/1.73m2) | 81.3 ± 13.9 | 76.8 ± 14.2 | 75.6 ± 14.3 | 64.1 ± 17.9 | <0.0001 |
| Serum phosphate (mg/dL) | 3.2 ± 0.4 | 3.2 ± 0.4 | 3.2 ± 0.4 | 3.2 ± 0.5 | 0.228 |
| Creatinine (mg/dL) | 9.3 ± 0.3 | 9.3 ± 0.4 | 9.3 ± 0.4 | 9.4 ± 0.4 | 0.0022 |
| Serum calcium (mg/dL) | 0.9 ± 0.2 | 1.0 ± 0.2 | 1 ± 0.2 | 1.2 ± 0.4 | <0.0001 |
| Serum cystatin C (mg/L) | 0.86 ± 0.18 | 0.91 ± 0.18 | 0.91 ± 0.18 | 1.09 ± 0.33 | <0.0001 |
| PASE score | 151.4 ± 70.8 | 149.1 ± 68.1 | 149.4 ± 67.3 | 139.8 ± 69.6 | 0.1117 |
| 6-Meter usual pace (m/sec) | 1.2 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.2 ± 0.2 | 0.0008 |
| Vitamin D supplements (IU) | 425.2 ± 256.7 | 396.2 ± 244.25 | 389.2 ± 249.4 | 344.3 ± 238.5 | 0.0003 |
| Calcium supplements (IU) | 1206.9 ± 634.3 | 1201.5 ± 592.4 | 1159.5 ± 587.5 | 1035.7 ± 568.0 | 0.0001 |
| White, n (%) | 269 (90.6) | 352 (92.9) | 313 (92.9) | 324 (87.6) | 0.0378 |
| Self-reported health status, n (%) | 256 (86.2) | 329 (86.8) | 296 (87.8) | 293 (79.4) | 0.006 |
| History of gout, n (%) | 13 (4.4) | 31 (8.2) | 13 (3.7) | 50 (13.5) | <0.0001 |
| History of fracture after age 50 years, n (%) | 83 (28.1) | 76 (20.1) | 75 (22.3) | 86 (23.3) | 0.2915 |
| Thiazide use, n (%) | 16 (5.5) | 30 (8.3) | 44 (14.0) | 89 (24.9) | <0.0001 |
| Loop diuretic use, n (%) | 7 (2.4) | 6 (1.67) | 15 (4.8) | 39 (10.9) | <0.0001 |
| Frail status | 0.0126 | ||||
| Robust, n (%) | 133 (44.8) | 169 (44.6) | 171 (50.7) | 148 (40) | |
| Pre-frail, n (%) | 137 (46.1) | 185 (48.8) | 143 (42.3) | 175 (47.3) | |
| Frail, n (%) | 27 (9.1) | 25 (6.6) | 23 (6.8) | 47 (12.7) | |